Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 90.18% is in line with its 5-year average of 86.02%, near the high end of its 5-year range (28.06%–100.00%).
2.35% above its 12-month average of 88.11%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 90.64%.
GROSS MARGIN
90.18%
GROSS MARGIN AVG TTM
88.11%
GROSS MARGIN AVG 3Y
84.56%
GROSS MARGIN AVG 5Y
86.02%
GROSS MARGIN AVG 10Y
92.19%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+2.35%
CURRENT VS 3Y AVG
+6.65%
CURRENT VS 5Y AVG
+4.83%
CURRENT VS 10Y AVG
-2.18%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
49.52%
median of 340 covered companies
CURRENT VS SECTOR MEDIAN
+82.11%
vs the sector median at left
Ascendis Pharma A/S
Market Cap
$14.16B
Gross Margin
90.18%
TTM Avg
88.11%
3Y Avg
84.56%
5Y Avg
86.02%
Market Cap
$14.97B
Gross Margin
32.24%
TTM Avg
31.70%
3Y Avg
34.15%
5Y Avg
35.17%
Market Cap
$13.19B
Gross Margin
98.30%
TTM Avg
98.34%
3Y Avg
98.50%
5Y Avg
98.50%
Market Cap
$15.24B
Gross Margin
54.69%
TTM Avg
54.56%
3Y Avg
56.03%
5Y Avg
57.27%
Market Cap
$12.95B
Gross Margin
93.35%
TTM Avg
96.31%
3Y Avg
90.48%
5Y Avg
92.91%
Market Cap
$12.89B
Gross Margin
21.85%
TTM Avg
27.90%
3Y Avg
28.49%
5Y Avg
28.39%
Market Cap
$12.52B
Gross Margin
30.08%
TTM Avg
33.76%
3Y Avg
35.72%
5Y Avg
36.84%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ascendis Pharma A/S (ASND) | $14.16B | 90.18% | 88.11% | 84.56% | 86.02% |
| Tempus AI, Inc. (TEM)vs › | $14.64B | 63.98% | 58.85% | 53.03% | 43.30% |
| Exelixis, Inc. (EXEL)vs › | $14.79B | 96.48% | 96.44% | 96.31% | 96.33% |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.97B | 32.24% | 31.70% | 34.15% | 35.17% |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 98.30% | 98.34% | 98.50% | 98.50% |
| Solventum Corporation (SOLV)vs › | $15.24B | 54.69% | 54.56% | 56.03% | 57.27% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $12.95B | 93.35% | 96.31% | 90.48% | 92.91% |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 21.85% | 27.90% | 28.49% | 28.39% |
| Baxter International Inc. (BAX)vs › | $12.52B | 30.08% | 33.76% | 35.72% | 36.84% |
| Penumbra, Inc. (PEN)vs › | $12.49B | 67.84% | 65.17% | 64.50% | 63.66% |
Gross Margin
90.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 90.64% |
| 2026-03-31 | 91.37% |
| 2025-12-31 | 88.91% |
| 2025-09-30 | 89.54% |
| 2025-06-30 | 80.10% |
| 2025-03-31 | 82.65% |
| 2024-12-31 | 91.94% |
| 2024-09-30 | 80.63% |
| 2024-06-30 | 68.15% |
| 2024-03-31 | 92.11% |
| 2023-12-31 | 85.87% |
| 2023-09-30 | 84.62% |
| 2023-06-30 | 72.72% |
| 2023-03-31 | 86.24% |
| 2022-12-31 | 77.67% |
| 2022-09-30 | 88.93% |
| 2022-06-30 | 82.37% |
| 2022-03-31 | 37.81% |
| 2021-12-31 | 28.06% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | -34507.85% |
| 2020-09-30 | -2223.50% |
| 2020-06-30 | -4327.44% |
| 2020-03-31 | -2484.94% |
| 2019-12-31 | 100.00% |
| 2019-09-30 | 100.00% |
| 2019-06-30 | -1264.87% |
| 2019-03-31 | 100.00% |
| 2018-12-31 | 100.00% |
| 2018-09-30 | 100.00% |
| 2018-06-30 | 100.00% |
| 2018-03-31 | 100.00% |
| 2017-12-31 | 100.00% |
| 2017-09-30 | 100.00% |
| 2017-06-30 | 100.00% |
| 2017-03-31 | 100.00% |
| 2016-12-31 | 100.00% |
| 2016-09-30 | 100.00% |
| 2016-06-30 | 100.00% |
| 2016-03-31 | 100.00% |
| 2015-12-31 | 100.00% |
| 2015-09-30 | 100.00% |
| 2015-06-30 | 100.00% |
| 2015-03-31 | 100.00% |
| 2014-12-31 | 100.00% |
| 2014-09-30 | 100.00% |
| 2014-06-30 | 100.00% |
| 2014-03-31 | 100.00% |
| 2013-12-31 | 100.00% |
| 2013-09-30 | 100.00% |
| 2013-06-30 | 100.00% |
| 2013-03-31 | 100.00% |
